Theseus Pharmaceuticals initiated with a Buy at Stifel

Stifel analyst Bradley Canino initiated coverage of Theseus Pharmaceuticals (THRX) with a Buy rating and $24 price target. The company’s Predictive Resistance Assay was validated by Deciphera’s (DCPH) INTRIGUE subgroup data published recently in January, the firm said. That data increases the likelihood that THE-630 achieves pan-KIT inhibition, the analyst contends, adding that the firm expects THE-630 to be "competitive as a late-comer" based on better convenience and tolerability.